Search Results
Results found for "Bongers BJ"
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
But that model is no longer sufficient. Cryptic Sites, Longer Onset: Why Some Drugs Work Differently in Cells Than in Assays One of the most You’ll walk away with tools to: Interpret probe-dependent effects Model and anticipate longer equilibration
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
You get longer activity with shorter exposure—a dream scenario for drug designers. The slow-offset compound stays on target longer, maintains therapeutic effect as concentrations drop, Persistent binding isn’t just about longer half-lives—it’s about smarter pharmacology.
- Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game
This case study highlights why computational chemistry is no longer a side tool—it’s a driver of discovery
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
because naloxone cannot reverse xylazine, the interventions that once worked for opioid overdoses are no longer And for policymakers, it’s a stark reminder: the U.S. no longer faces a “fentanyl crisis”—it faces a
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, et al.
- Advantages of Fluorescent Probes in GPCR Assays
combination of the correct linker and dye can offer better photostability, maintaining signal integrity for longer This can be fixed by using fluorescent dyes that emit at longer wavelengths, where fluorescence from
- TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi
evidenced that 5-HT4/6/7-Gs coupled receptors have a cytosolic TM5 that is on average 5.7 residues longer regions of 27 class A GPCRs coupled to Gs or Gi/o yielded similar results, TM5 was 5.6 ± 1.5 residues longer
- G protein-coupled receptors that influence lifespan of human and animal models
Humanity has always sought to live longer and for this, multiple strategies have been tried with varying
- From Pharmacy Crisis to Scientific Calling: Catherine Demery’s Unfiltered Path into Opioid Research
Watch Episode 172 What happens when the career you planned no longer feels right?
- Why “Displacement” Misleads You: Allosteric Binding Demystified
You’re no longer tracking the same protein species—and that changes everything.
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
The work no longer felt like an assignment—it felt like a calling.
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
shapes your entire pipeline trajectory—and understanding when equilibrium affinity falls short is no longer
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
receptor signaling kinetics and concentration-dependent responses using ONE-GO biosensors Why wait any longer
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Gain a competitive edge: Learn to leverage restricted diffusion and rebinding to create drugs with longer
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
essential advancement will be the integration of DMS with emerging sequencing technologies that allow for longer
- Unlocking Cell's Secrets: Spontaneous β-Arrestin-Membrane Preassociation Drives Receptor-Activation
The above causes β-arrestin molecules to stay longer and accumulate on the plasma membrane, allowing
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
For this reason, DL models generally require more computational resources (such as powerful GPUs) and longer
- Molecular basis for ligand modulation of the cannabinoid CB 1 receptor
ARTICLES: This article is part of a themed issue on Structure Guided Pharmacology of Membrane Proteins (BJP
